(IN BRIEF) Sanofi has announced positive phase 2 clinical results for lunsekimig, a novel bispecific therapy targeting key inflammatory pathways in respiratory diseases. The treatment successfully met primary and key secondary endpoints in studies involving moderate-to-severe asthma and chronic rhinosinusitis … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged asthma treatment, atopic dermatitis, biologic therapy, chronic rhinosinusitis with nasal polyps, clinical trials, CRSwNP, drug development, Houman Ashrafian, IL13, lunsekimig, Nanobody VHH, Phase 2 study, respiratory diseases, Sanofi, Sanofi Advances Respiratory Pipeline with Promising Clinical Data for Dual Targeting Lunsekimig Therapy, Sanofi Reports Positive Phase 2 Results for Lunsekimig in Asthma and Respiratory Diseases Development, TSLP
(IN BRIEF) GSK has secured approval in China for Exdensur (depemokimab), a first-of-its-kind ultra-long-acting biologic for treating severe eosinophilic asthma in patients aged 12 and above. Approved by China’s National Medical Products Administration, the therapy offers a novel treatment approach … Read the full press release
Posted in Business, Healthcare, Marketing, Pharma & Biotech, Science, United Kingdom
Tagged asthma exacerbations, asthma treatment, biologic therapy, biologics, China healthcare, chronic rhinosinusitis with nasal polyps, clinical trials, CRSwNP, Depemokimab, eosinophilic asthma, Exdensur, GSK Advances Asthma Treatment Innovation with NMPA Approval of Exdensur for Eosinophilic Severe Asthma in China, GSK Introduces Ultra-Long-Acting Biologic Exdensur to Address Severe Asthma Burden in China Healthcare System, GSK plc, Kaivan Khavandi, National Medical Products Administration, NMPA, respiratory disease, Severe Asthma, SWIFT-1 trial, SWIFT-2 trial, type 2 inflammation
(IN BRIEF) GSK announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults in the EU with uncontrolled COPD characterised by raised blood eosinophils who are already receiving inhaled triple therapy, making it the … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged American Thoracic Society, blood eosinophils, COPD, CRSwNP, EGPA, emergency department visits, eosinophilic phenotype, European Commission, European Federation of Allergy and Airways Diseases Patients’ Associations, Exacerbations, GSK, GSK Expands Nucala’s European Indications with Landmark Approval for Uncontrolled COPD, GSK Strengthens Its Respiratory Portfolio as Nucala Receives EU Approval for Add-On COPD Treatment, HES, hospitalisations, IL-5, inhaled triple therapy, Kaivan Khavandi, MATINEE trial, mepolizumab, New England Journal of Medicine, Nucala, Phase III, respiratory medicine, Severe Asthma, Susanna Palkonen, type 2 inflammation
(IN BRIEF) GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s Ministry of Health, Labour and Welfare, the therapy delivers sustained disease control … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ANCHOR trials, asthma exacerbations, chronic rhinosinusitis with nasal polyps, CRSwNP, Depemokimab, Exdensur, Exdensur Gains Approval in Japan, Expanding GSK’s Respiratory Biologic Portfolio, GSK, GSK’s Depemokimab Approved in Japan, interleukin 5, Introducing New Option for Severe Asthma Care, Japan Ministry of Health Labour and Welfare, Kaivan Khavandi, Nasal Polyps, respiratory medicine, Severe Asthma, SWIFT trials, type 2 inflammation, ultra long acting biologic
Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged asthma, atopic dermatitis, CRSwNP, dermatological diseases, dupilumab, Dupixent, extreme itch, George D. Yancopoulos, inflammatory skin disease, Naimish Patel, nodules, persistent itch, prurigo nodularis, Regeneron, respiratory diseases, skin diseases, skin lesions, unbearable itch
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?